Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.
About Debio R.P.
Debio Recherche Pharmaceutique (Debio R.P.), based in Martigny ( Switzerland), is a pharmaceutical research, development and production company that has been Swissmedic and ANVISA ( Brazil) certified, as well as inspected and registered by the American Food and Drug Administration (FDA) and the KFDA ( South Korea). Debio R.P. is active in the discovery, formulation and development of peptides. Debio R.P. forms part of Debiopharm Group™ and employs 130 people, half of whom are university graduates or engineers.About Dr. Reddy's Dr. Reddy's Laboratories Ltd. (NYSE: RDY) (Dr. Reddy's) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: http://www.drreddys.com Debiopharm S.A. Contact Maurice Wagner Director Corporate Affairs & Communication Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 email@example.com Dr. Reddy' s Contact S. Rajan firstname.lastname@example.org Tel.: +91-40-49002445 Additional Media Contacts In London Maitland Brian Hudspith Tel.: +44(0)20-7379-5151 email@example.com In New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive Tel.: +1-212-845-4292 Fax: +1-212-845-4260 firstname.lastname@example.org Investors and Financial Analysts: Kedar Upadhye email@example.com Tel.: +91-40-66834297 Saunak Savla firstname.lastname@example.org Tel.: +91-40-49002135 Milan Kalawadia ( USA) email@example.com Tel.: +1-908-203-4931 SOURCE The Debiopharm Group
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts